STOCK TITAN

YS Biopharma Co., Ltd. Ordinary Shares - YS STOCK NEWS

Welcome to our dedicated page for YS Biopharma Co., Ltd. Ordinary Shares news (Ticker: YS), a resource for investors and traders seeking the latest updates and insights on YS Biopharma Co., Ltd. Ordinary Shares stock.

YS Biopharma Co., Ltd. (Nasdaq: YS) is a global biopharmaceutical company focused on discovering, developing, manufacturing, and delivering next-generation vaccines and therapeutic biologics for infectious diseases and cancer. Operating in China, the United States, Singapore, and the Philippines, YS Biopharma leverages its proprietary PIKA® immunomodulating technology platform to create innovative solutions for diseases such as rabies, coronavirus, hepatitis B, influenza, and shingles.

The company recently announced changes to its board of directors and key strategic appointments within its wholly-owned subsidiaries in China. Notable changes include the resignation of Mr. Bo Tan and Mr. Shaojing Tong from the board and the appointment of Ms. Chunyuan Wu as the new legal representative and executive director of Beijing Yisheng Biotechnology Co., Ltd.

YS Biopharma is also making significant strides in its financial performance, having fully repaid a $40,000,000 loan, which enhances its financial strength and flexibility. The company continues to advance its product pipeline, achieving positive interim results from a Phase 3 clinical trial of its PIKA Rabies Vaccine, which promises accelerated protection and a shorter regimen compared to conventional vaccines.

In terms of financial health, YS Biopharma reported revenues of RMB438.1 million ($61.9 million) for the first nine months of fiscal 2024. Despite challenges such as supply chain disruptions, the company maintained strong market leadership in rabies vaccines in China, with an estimated double-digit year-over-year growth in product sales during the fourth quarter of fiscal 2024.

Additionally, the company's YS-HBV-002 immunotherapeutic vaccine for chronic hepatitis B virus (HBV) infection received clinical trial approval from the Philippine FDA, with a Phase I clinical trial set to begin in June 2024.

YS Biopharma recently announced it would change its legal name to LakeShore Biopharma Co., Ltd., effective May 28, 2024, to better align with its global market positioning. The company's ordinary shares and warrants will continue to trade on Nasdaq under the new ticker symbols 'LSB' and 'LSBPW', respectively.

For more detailed information, visit investor.ysbiopharma.com.

Rhea-AI Summary
YS Biopharma Co., Ltd. (NASDAQ: YS) reported unaudited financial results for the first half of fiscal year 2024, with Dr. David Shao, the Director, President, and CEO, addressing the lingering impact of inventory issues from COVID-related disruptions at their YSJA rabies vaccine manufacturing facilities. However, operational enhancements have been made to overcome setbacks, resulting in a return to normal vaccine production and an improvement in inventory levels. The company expects a 50% increase in YSJA rabies vaccine revenues in the third quarter of fiscal year 2024. Product candidates are advancing in development, signaling optimism for the future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
-
Rhea-AI Summary
YS Biopharma Co., Ltd. (NASDAQ: YS) announced the appointment of Ms. Rui Yu as the new Chairperson of its Audit Committee, as a member of its Compensation Committee, and as a member of the Nominating and Corporate Governance Committee. Ms. Yu brings extensive experience in the healthcare and finance sectors, having previously held positions at Oceanpine Capital, China Renaissance Group, and Gerson Lehman Group. Her educational background includes degrees from Guangdong Pharmaceutical University, the University of Missouri School of Medicine, and the University of Chicago Booth School of Business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7%
Tags
none
-
Rhea-AI Summary
YS Biopharma Co., Ltd. (NASDAQ: YS) responds to unauthorized press release, clarifies board composition and meeting misinformation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.33%
Tags
none
Rhea-AI Summary
YS Biopharma Co., Ltd. (NASDAQ: YS) will hold an extraordinary general meeting of shareholders on December 28, 2023, to vote on the removal and appointment of directors. The record date for shareholders entitled to receive notice is December 20, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
none
-
Rhea-AI Summary
No press release available for the given story.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
none
-
Rhea-AI Summary
YS Biopharma Co., Ltd. (NASDAQ: YS) announces Noble Capital Markets' initiation of equity research coverage with an 'Outperform' rating and a 12-month price target of US$5.25 per share. The report highlights the PIKA Immunomodulating Platform, significant opportunities in the anti-viral and immuno-oncology markets, and the commercialized rabies vaccine. Noble's price target is based on FY2029 EPS of RMB6.93 ($0.95), discounted at 30% and applying a Nasdaq earnings multiple of 20x.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
none
Rhea-AI Summary
YS Biopharma completes subject enrollment in Phase 3 clinical trial of PIKA Rabies Vaccine. The trial includes 4,500 subjects and aims to assess safety, immunogenicity, and lot-to-lot consistency. The vaccine utilizes proprietary PIKA adjuvant technology, showing strong immunogenicity in previous trials. The PIKA Rabies Vaccine has the potential to achieve accelerated protection and replace conventional regimens.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
-
Rhea-AI Summary
YS Biopharma has received a Deficiency Letter from Nasdaq, indicating that its closing bid price has been below $1.00 per share for the last 31 consecutive business days. The Company has a compliance period of 180 calendar days to regain compliance. If it fails to do so, it may be eligible for an additional 180 calendar days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15%
Tags
none
-
Rhea-AI Summary
YS Biopharma enrolls first subject in Phase 3 trial of PIKA Rabies Vaccine, expected to include 4,500 subjects. Previous trials show safety and strong immunogenicity. Potential to achieve best-in-class accelerated protection. Positive outlook for future vaccine interventions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
Rhea-AI Summary
YS Biopharma receives patent for PIKA YS-HBV-002 vaccine for chronic HBV infection
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
none

FAQ

What is the current stock price of YS Biopharma Co., Ltd. Ordinary Shares (YS)?

The current stock price of YS Biopharma Co., Ltd. Ordinary Shares (YS) is $1.02 as of May 24, 2024.

What is the market cap of YS Biopharma Co., Ltd. Ordinary Shares (YS)?

The market cap of YS Biopharma Co., Ltd. Ordinary Shares (YS) is approximately 192.1M.

What does YS Biopharma specialize in?

YS Biopharma specializes in discovering, developing, manufacturing, and delivering vaccines and therapeutic biologics for infectious diseases and cancer.

Where does YS Biopharma operate?

YS Biopharma operates in China, the United States, Singapore, and the Philippines.

What is the PIKA® technology platform?

The PIKA® technology platform is YS Biopharma's proprietary immunomodulating technology used to develop next-generation vaccines and biologics.

What recent changes have been made to the board of directors?

Mr. Bo Tan and Mr. Shaojing Tong have resigned from the board, and Ms. Chunyuan Wu has been appointed as the new legal representative and executive director of Beijing Yisheng Biotechnology Co., Ltd.

What are the latest financial achievements of YS Biopharma?

YS Biopharma recently fully repaid a $40,000,000 loan and reported revenues of RMB438.1 million ($61.9 million) for the first nine months of fiscal 2024.

What are the key products in YS Biopharma's pipeline?

Key products include the PIKA Rabies Vaccine, PIKA YS-ON-001, and the YS-HBV-002 immunotherapeutic vaccine for chronic hepatitis B.

Has YS Biopharma received any recent regulatory approvals?

Yes, YS Biopharma's YS-HBV-002 vaccine received clinical trial approval from the Philippine FDA.

What is the new name of YS Biopharma?

The new name of YS Biopharma is LakeShore Biopharma Co., Ltd.

Will the ticker symbol of YS Biopharma change?

Yes, the ticker symbol will change to 'LSB' for ordinary shares and 'LSBPW' for warrants, effective May 28, 2024.

How can I get more information about YS Biopharma?

For more information, visit the company's investor relations website at investor.ysbiopharma.com.

YS Biopharma Co., Ltd. Ordinary Shares

Nasdaq:YS

YS Rankings

YS Stock Data

192.09M
188.33M
81.43%
2.85%
0.02%
Biotechnology
Healthcare
Link
United States of America
Beijing